Anesthesia for patients with pulmonary hypertension

Current Opinion in Anaesthesiology

Volumn 23, Issue 3, 2010, Pages 411-416

  Pritts, Chad D ^a   Pearl, Ronald G ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Anesthesia; Pulmonary hypertension; Right heart failure; Vasodilators

Indexed keywords

ADENOSINE; AMPHETAMINE DERIVATIVE; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CALCIUM CHANNEL BLOCKING AGENT; DEXFENFLURAMINE; DOBUTAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ETOMIDATE; FENFLURAMINE; ILOPROST; MILRINONE; NITRIC OXIDE; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTANOID; RAPESEED OIL; TRANSFORMING GROWTH FACTOR BETA; UNIPROST; VASOPRESSIN; WARFARIN;

ANESTHESIA; ANESTHESIA INDUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTINUOUS INFUSION; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOTENSION; HYPOXIA; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; MORTALITY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SURGICAL RISK; SYSTEMIC VASCULAR RESISTANCE;

ANESTHESIA; BLOOD PRESSURE; HUMANS; HYPERTENSION, PULMONARY; VASODILATOR AGENTS;

EID: 77951987401     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32833953fb     Document Type: Review

References (54)

1. Humbert M, McLaughlin VV. The 4th World Symposium on Pulmonary • Hypertension. J Am Coll Cardiol 2009; 54: S1-S2. An overview of this pivotal conference which will affect all aspects of the management of patients with pulmonary hypertension.
2. Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and •• treatment of nonpulmonary arterial hypertension, pulmonary hypertension. J Am Coll Cardiol 2009; 54: S85-S96. Management of the patient with pulmonary hypertension in groups 2-5 of the new classification ('non-PAH pulmonary hypertension') differs significantly from that of patients with PAH.
3. Barst RJ, Gibbs SR, Ghofrani HA, et al. Updated evidence-based treatment •• algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-S84. The newest evidence-based treatment recommendations for the management of PAH.
4. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and • treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537. Superb evidence-based guidelines on pulmonary hypertension which include clinical classification, diagnosis, evaluation, and therapy.
5. McLaughlin VV, Archer SL, Badesch DB, et al. ACC/AHA 2009 expert •• consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association. Circulation 2009; 119: 2250-2294. This consensus document representing four different societies is a comprehensive summary of pathology, pathogenesis, classification, natural history, diagnostic assessment, and evidence-based treatment of pulmonary hypertension, including both PAH and other forms of pulmonary hypertension.
6. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure • during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34: 888-894. The new definition of pulmonary hypertension is based on this review demonstrating that normal mPAP is 14.0±3.3mmHg but can increase significantly above 30mmHg during exercise.
7. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of •• pulmonary hypertension. J Am Coll Cardiol 2009; 54: 43-54. This article describes the most recent scheme (from the 2008 Fourth World Symposium) for the clinical classification of pulmonary hypertension, including the rationale for the changes from prior classifications.
8. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of • pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (1 Suppl) : S32-S42. Genetic abnormalities, particularly mutations in the BMPR2 gene, account for a substantial number of patients with PAH.
9. Geraci MW, Bull TM, Tuder RM. Genomics of pulmonary arterial hypertension: implications for therapy. Heart Fail Clin 2010; 6: 101-114.
10. Sitbon O, Lascoux-Combe C, Delfraissy JF, et al. Prevalence of HIV related • PAH in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177: 1133-1141. Despite effective antiretroviral therapy, the prevalence of HIV remains at 0.46% and has not decreased.
11. Ramsay M. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol 2010 [Epub ahead of print].
12. Beghetti M, Galie N. Eisenmenger syndrome: a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 733-740.
13. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 53: 1211-1218.
14. Weitzenblum E, Chaouat A, Canuet M, Kessler R. Pulmonary hypertension in • chronic obstructive pulmonary disease and interstitial lung diseases. Semin Respir Crit Care Med 2009; 30: 458-470. Although pulmonary hypertension due to COPD and interstitial lung disease is usually only mild to moderate in severity, it is associated with a markedly decreased prognosis.
15. Roscoe A, Klein A. Pulmonary endarterectomy. Curr Opin Anaesthesiol 2008; 21: 16-20.
16. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of • treatment in pulmonary hypertension. J Am Coll Cardiol 2009; 54: S67-S77. Pulmonary endarterectomy for CTEPH, atrial septostomy, bilateral sequential lung or heart-lung transplantation, and RV assist devices can be successful interventions in patients with severe pulmonary hypertension.
17. Badesch DB, Champion HC, Sanchez M A G, et al. Diagnosis and assessment •• of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-S66. The recommendations for diagnosis and assessment of PAH from the Fourth World Symposium.
18. Halpern SD, Taichman DB. Misclassification of pulmonary hypertension due • to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009; 136: 37-43. In a large series of patients with pulmonary hypertension, over half the patients with a pulmonary capillary wedge pressure 15mmHg or less had an LVEDP greater than 15mmHg and would have been presumed to have PAH based on PCWP alone rather than pulmonary hypertension due to left heart disease.
19. Minai OA, Ricaurte B, Kaw R, et al. Frequency and impact of pulmonary • hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol 2009; 104: 1300-1306. Pulmonary hypertension is common among patients with obstructive sleep apnea and results in functional limitations and increased mortality. Estimation of RV systolic pressure by echocardiography is frequently inaccurate.
20. Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardio-•• graphy in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-621. Although Doppler echocardiography is frequently used for noninvasive assessment of right ventricular pressure in patients with or at risk for pulmonary hypertension, significant overestimation or underestimation occurred in almost half the patients.
21. Cacciapuoti F. Echocardiographic evaluation of right heart function and • pulmonary vascular bed. Int J Cardiovasc Imaging 2009; 25: 689-697. Newer echocardiographic measurements can provide better evaluation of right ventricular function in patients with pulmonary hypertension.
22. McLure LE, Peacock AJ. Cardiac magnetic resonance imaging for the • assessment of the heart and pulmonary circulation in pulmonary hypertension. Eur Respir J 2009; 33: 1454-1466. Cardiac MRI provides a morphological and functional assessment of the right ventricle and the pulmonary circulation and may become the primary modality for evaluation of patients with pulmonary hypertension.
23. Revel MP, Faivre JB, Remy-Jardin M, et al. Pulmonary hypertension: ECG-gated 64-section CT angiographic evaluation of new functional parameters as diagnostic criteria. Radiology 2009; 250: 558-566.
24. Tonelli AR, Alnuaimat H, Mubarak K. Pulmonary vasodilator testing and use of • calcium channel blockers in pulmonary arterial hypertension. Respir Med [Epub ahead of print]. A recent review of the literature regarding pulmonary vasodilator testing and use of calcium channel blockers in PAH.
25. Greyson CR. Pathophysiology of right ventricular failure. Crit Care Med 2008; • (1 Suppl) : S57-S65. Right ventricular failure in the critical care setting commonly involves a combination of pressure overload and decreased contractility, requiring management markedly different from left ventricular failure.
26. Afifi S, Shayan S, Al-Qamari A. Pulmonary hypertension and right ventricular function: interdependence in pathophysiology and management. Int Anesthesiol Clin 2009; 47: 97-120.
27. Bogaard HJ, Abe K, Noordegraaf AV, Voelkel NF. The right ventricle under pressure cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest 2009; 135: 794-804.
28. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of • pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-S31. A comprehensive review of the multiple mechanisms responsible for the functional and structural changes in the pulmonary vasculature in PAH, with an emphasis on endothelial dysfunction, activation of fibroblasts and smooth muscle cells, cross-talk between cells within the vascular wall, and recruitment of circulating progenitor cells.
29. Yildiz P. Molecular mechanisms of pulmonary hypertension. Clin Chim Acta 2009; 403: 9-16.
30. Lurz P, Nordmeyer J, Coats L, et al. Immediate clinical and haemodynamic • benefits of restoration of pulmonary valvar competence in patients with pulmonary hypertension. Heart 2009; 95: 646-650. Percutaneous pulmonary valve implantation produces clinical and hemodynamic improvement in patients with severe pulmonary regurgitation and pulmonary hypertension associated with congenital heart disease.
31. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled •• trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403. A meta-analysis of 21 randomized controlled trials of prostanoids, endothelinreceptor antagonists, and phosphodiesterase type-5 inhibitors in PAH demonstrated a 43% reduction in mortality.
32. Gessler T, Seeger W, Schmehl T. Inhaled prostanoids in the therapy of • pulmonary hypertension. J Aerosol Med Pulm Drug Deliv 2008; 21: 1-12. Inhaled prostacyclin and prostacyclin analogs (such as iloprost) are effective in producing selective pulmonary vasodilation and improving outcome in patients with pulmonary hypertension.
33. Vassallo FG, Kodric M, Scarduelli C, et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur J Intern Med 2009; 20: 24-29.
34. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary •• arterial hypertension. N Engl J Med 2009; 361: 1864-1871. A case-based discussion of the use of sildenafil and other PDE-5 inhibitors for PAH.
35. Gailie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
36. Jing ZC, Jiang X, Wu BX, et al. Vardenafil therapy for patients with pulmonary arterial hypertension. A one year, multicenter, open-label study. Heart 2009; 95: 1531-1536.
37. Ajami GH, Borzoee M, Radvar M, Amoozgar H. Comparison of the effectiveness of oral sildenafil versus oxygen administration as a test for feasibility of operation for patients with secondary pulmonary arterial hypertension. Pediatr Cardiol 2008; 29: 552-555.
38. Hill NS, Roberts KR, Preston IR. Postoperative pulmonary hypertension: • etiology and treatment of a dangerous complication. Respir Care 2009; 54: 958-968. Postoperative pulmonary hypertension has high morbidity and mortality and treatment requires an understanding of the pathophysiology and available treatment options.
39. Price LC, Montani D, Jaïs X, et al. Noncardiothoracic nonobstetric surgery in •• mild-moderate pulmonary hypertension: perioperative management of 28 consecutive individual cases, Eur Respir J [Epub ahead of print]. In a series of 28 patients with mostly nonsevere pulmonary hypertension (75% functional class 1 or 2, 25% class 3, and no patients in class 4) and a large proportion of minor surgical procedures (43%) and regional anesthesia (50%), perioperative complications related to pulmonary hypertension occurred in 29% of all patients and four of the 28 patients (14%) died. Emergency procedures, major surgery and long operations were associated with increased risk.
40. Ross AF, Ueda K. Pulmonary hypertension in thoracic surgical patients. Curr • Opin Anaesthesiol 2010; 23: 25-33. Management of patients with pulmonary hypertension undergoing thoracic surgery requires identification of potential problem areas such as one-lung ventilation and knowledge of new pharmacological options, particularly inhaled vasodilators.
41. Pedoto A, Amar D. Right heart function in thoracic surgery: role of echocardiography. Curr Opin Anaesthesiol 2009; 22: 44-49.
42. Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made • on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009; 30: 256-265. Although maternal mortality in parturients with PAH remains prohibitively high (25%), it has improved from the 38% mortality rate in the period from 1978 to 1996.
43. Madden BP. Pulmonary hypertension and pregnancy. Int J Obstet Anesth • 2009; 18: 156-164.
44. Higton AM, Whale C, Musk M, Gabbay E. Pulmonary hypertension in pregnancy: two cases and review of the literature. Intern Med J 2009; 39: 766-770.
45. Fox C, Kalarickal PL, Yarborough MJ, Jin JY. Perioperative management including new pharmacological vistas for patients with pulmonary hypertension for noncardiac surgery. Curr Opin Anaesthesiol 2008; 21: 467-472.
46. Gordon C, Collard CD, Pan W. Intraoperative management of pulmonary • hypertension and associated right heart failure. Curr Opin Anaesthesiol 2009; 23: 49-56. Intraoperative management of patients with pulmonary hypertension requires knowledge of pathophysiology and available treatment modalities.
47. Friesen RH, Williams GD. Anesthetic management of children with pulmonary • arterial hypertension. Paediatr Anaesth 2008; 18: 208-216. Perioperative pulmonary hypertension is a frequent problem in pediatric anesthesia and requires an understanding of issues specific to the pediatric population.
48. Teo YW, Greenhalgh DL. Update on anaesthetic approach to pulmonary hypertension. Eur J Anaesthesiol 2010 [Epub ahead of print].
49. Forrest P. Anaesthesia and right ventricular failure. Anaesth Intensive Care 2009; 37: 370-385.
50. Wang H, Gong M, Zhou B, Dai A. Comparison of inhaled and intravenous • milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. Adv Ther 2009; 26: 462-468. Following cardiopulmonary bypass, inhaled milrinone had similar pulmonary vasodilation to intravenous milrinone, but inhaled milrinone improved shunt fraction and did not produce hypotension and systemic vasodilation.
51. Winterhalter M, Simon A, Fischer S, et al. Comparison of inhaled iloprost and • nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: a prospective randomized trial. J Cardiothorac Vasc Anesth 2008; 22: 406-413. Although both inhaled nitric oxide and inhaled iloprost were effective in decreasing pulmonary hypertension after weaning from cardiopulmonary bypass, iloprost was significantly more effective.
52. Ewert R, Schäper C, Halank M, et al. Inhalative iloprost: pharmacology and clinical application. Exp Opin Pharmacother 2009; 10: 2195-2207.
53. Creagh-Brown BC, Griffiths MJ, Evans TW. Bench-to-bedside review: inhaled nitric oxide therapy in adults. Crit Care 2009; 13: 221.
54. Boffini M, Sansone F, Ceresa F, et al. Role of oral sildenafil in the treatment of right ventricular dysfunction after heart transplantation. Transplant Proc 2009; 41: 1353-1356.